Heat Waves Are a Growing Threat to Europe's Nuclear Power Supply
Weather-related nuclear outages, mainly caused by elevated temperatures of cooling water, increased threefold in the period from 2010 to 2019, compared with 1990 to 2009, according to a study published in Energy Economics. Due to climate change, the intensity and length of these heat waves is expected to increase.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
18 minutes ago
- The Verge
What's the point of a plastics treaty?
Posted Aug 11, 2025 at 7:27 PM UTC Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates. Justine Calma Posts from this author will be added to your daily email digest and your homepage feed. See All by Justine Calma Posts from this topic will be added to your daily email digest and your homepage feed. See All Climate Posts from this topic will be added to your daily email digest and your homepage feed. See All Environment Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Policy Posts from this topic will be added to your daily email digest and your homepage feed. See All Science
Yahoo
an hour ago
- Yahoo
Perseids meteor shower 2025 will peak Tuesday night: When and where to watch the year's brightest shower
The Perseids is considered the best, most visible meteor shower of the year, according to NASA. The Perseids meteor shower will peak Tuesday night into Wednesday morning, with up to 100 streaks visible every hour. The Perseids shower, which has been active since July 17, is 'considered the best meteor shower of the year,' according to NASA. Experts note that the moon may impact some visibility, but viewers will still be able to watch the shower if they're in a dark area away from city lights and their phones. Here's what to know to prepare for the year's biggest meteor shower. What is a meteor shower? Meteoroids are falling pieces of debris from comets and asteroids that, as they enter the Earth's atmosphere, turn into meteors, according to NASA. As meteors vaporize, their trails are visible from Earth, which is what we call 'shooting stars' or 'falling stars.' A meteor shower is what happens when there's a higher-than-usual number of meteors falling across the sky in a short period of time. Meteor showers happen at certain times throughout the year because comets also orbit the sun, so when a comet and the Earth cross paths, the Earth encounters a lot of the comet's debris, or meteoroids. What to know about the Perseids meteor shower The Perseids meteors leave particularly long, bright trails as they fall through Earth's atmosphere, with about 50 to 100 streaks expected to be visible every hour at its peak. The Perseids shower comes from comet 109/Swift-Tuttle, a comet that takes 133 years to orbit the sun and crosses the Earth's orbit once a year. The shower's name comes from the constellation Perseus, NASA explains, which is the point in the sky from which the Perseids meteors are visibly falling. Fireballs are also anticipated to appear throughout Tuesday night into Wednesday. 'Fireballs' is an astronomical term used by NASA to describe meteoroids that burst into bright colors while in the Earth's atmosphere, becoming more visible than average meteors. How to watch the Perseids meteor shower Northern Hemisphere residents will have the best Perseids views, NASA reports. But this year's shower does coincide with the rise of a waning gibbous moon, the phase between a full moon and a half moon, which could impact visibility, warned. To find the best time to see the Perseids shower where you are, check the Global Meteor Network's meteor-tracking meter.
Medscape
an hour ago
- Medscape
Coronary Sinus Reducer Shows Promise, With Caveats
The coronary sinus reducer, an hourglass-shaped stent that narrows the coronary sinus to increase coronary sinus pressure, has shown some promise in treating patients with refractory angina. But a meta-analysis published today in JACC: Cardiovascular Interventions found the benefits of the intervention are likely smaller than those early studies predicted. 'There have been lots of unblinded single-arm studies [of the procedure] but only three randomized controlled trials, so we wanted to look at the different effect sizes to better understand the overall potential efficacy,' said Rasha Al-Lamee, MD, a cardiologist at the National Heart and Lung Institute, part of Imperial College London, London, England, who led the meta-analysis. Al-Lamee and her colleagues looked at data from a combined total of 180 patients in the three trials, as well as 13 single-arm studies with 668 total patients. They found the coronary sinus procedure to be safe, with a success rate of 98.3%. But while both the single-arm and the controlled trials demonstrated improvements in symptoms of angina, the effect size was much smaller in the controlled trials. In the more rigorous trials, 26% of patients experienced at least a one-class improvement and 17% had at least a two-class improvement on the Canadian Cardiovascular Society classification of angina. Those figures were about one third of the gains reported in the single-arm trials. What's more, the randomized controlled trials found no evidence of benefit based on continuous measurements such as the Seattle Angina Questionnaire. Nor did they find improvements in objective measures such as myocardial perfusion associated with the intervention. Deepak Bhatt, MD, a cardiologist at the Icahn School of Medicine at Mount Sinai in New York City, who co-wrote an editorial accompanying the journal article, said more treatment options are needed for patients with refractory angina, who have often exhausted all other medical therapies and surgical procedures. But while coronary sinus reduction shows promise, the meta-analysis demonstrates why more, and larger, trials will be needed before clinicians can use it more broadly. 'It's not an inexpensive procedure, so we want substantial, objectively quantified evidence that it helps patients,' he told Medscape Medical News . 'History is littered with examples of things we were convinced worked but really didn't.' Percutaneous laser therapy, for example, seemed to show benefits for refractory angina at first, but more rigorous randomized trials found no benefit from the procedure, he said. The coronary sinus reducer device is already approved in the UK and Europe and its use is on the rise there, said Al-Lamee, but it has not yet been approved in the US. The ongoing COSIRA-II trial, with an estimated enrollment of 380 patients, should be well-powered enough to provide definitive results and support US approval, she said. Should COSIRA-II show definite benefit, she added, the device may become more of a frontline treatment, used before riskier revascularization options. 'Why have a redo of coronary artery bypass surgery if you have a device that is safe and effective?' she said. Al-Lamee had received consulting and speaker fees from Shockwave Medical, which makes the CSR device. Bhatt reported no relevant financial conflicts.
